No Data
No Data
No Data
Algorae Harnessing AI to Meet Acute Medical Needs
Fixed-dose combination drugs hold several advantages over individual treatments as they can be effective against a wider range of targets or diseases.
Algorae Pharmaceuticals' AI-116 Dementia Treatment Shows Promising Pre-clinical Results
Algorae Pharmaceuticals (ASX: 1AI) has released positive results from in vitro pre-clinical studies to assess AI-116 for the treatment of neurodegenerative disorders, including those characterised by dementia.
Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform
Algorae Pharmaceuticals (ASX:1AI) said it expects the first version of its AlgoraeOS platform to become operational by the third quarter. AlgoraeOS was developed in collaboration with AI experts from
Algorae Pharmaceuticals Advances Artificial Intelligence Drug Prediction Platform
Algorae Pharmaceuticals (ASX: 1AI) provided an update today on how it is advancing artificial intelligence (AI) biopharmaceutical prediction platform.
Algorae Pharmaceuticals Considers Combination Therapy for NTCELL Trial
Algorae Pharmaceuticals (ASX:1AI) is considering using a combination therapy for the third clinical trial of its NTCELL implanted therapy. The pharmaceutical company is looking at combining the therap
Algorae Pharmaceuticals to Use AI Platform to Build up Drug Candidate Pipeline
Algorae Pharmaceuticals (ASX: 1AI) has taken big strides in the December quarter to grow out its artificial intelligence (AI) drug discovery and development platform.
No Data